Quarterly Results
AEHR Earnings Forecast
Looking ahead, AEHR remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2026/Q3 project quarter revenue of 16.24M and an EPS of 0.02.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2026 have been Revise Upward by 0.63%, while EPS estimates have been No Change by 0%. For the upcoming Q2 2026, revenue estimates have been adjusted Revise Upward by 1.15% . These revisions correlate with a 12.05% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in AEHR long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Al Analysis
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how AEHR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AEHR sees a -0.42% change in stock price 10 days leading up to the earnings, and a -0.62% change 10 days following the report. On the earnings day itself, the stock moves by -0.63%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in NOV/2025, the stock changed 15.95% on the day following the earnings release and then changed by 15.95% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of AEHR's latest earnings report for ?
AEHR reported its earnings on 2026-01-08, showcasing a revenue of 9.88M against an estimate of 11.05M, resulting in a -10.55% surprise. The EPS was -0.04, surpassing the expected -0.08 by 50% . The stock experienced a 15.95% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.
How did AEHR's stock price react after the earnings release?
Following AEHR's earnings announcement on 2026-01-08, the stock price moved by 15.95% on the day of the release. Over the subsequent five days, it saw a % change. Historically, AEHR's stock price tends to shift by an average of -0.42% in the 10 days leading up to earnings and -0.62% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for AEHR for 2026/Q3?
For 2026/Q3, analysts estimate AEHR’s annual revenue to reach 16.24M, while the EPS is projected at 0.02. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.63% and EPS estimates Revise Upward by 1.15% over the past three months, indicating analyst expectation in the company’s performance.
How does AEHR's stock price correlate with earnings forecast revisions?
The correlation between AEHR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2026 were Revise Upward by 0.63%, while EPS estimates moved Revise Upward by 1.15% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from AEHR's next earnings report?
Based on historical trends, AEHR's stock price typically moves by -0.42% in the 10 days before its earnings and -0.62% in the 10 days after. For the upcoming 2026/Q3 earnings, analysts expect an EPS of 0.02 and revenue of 16.24M.
What is the sentiment in Aehr Test Systems (AEHR) Q2 2026 Earnings Call Summary?
The earnings call reveals a significant decline in revenue and gross margin, with a net loss reported. Management's vague responses in the Q&A add uncertainty. Despite positive long-term prospects in AI and strategic partnerships, the immediate financial performance and unclear guidance suggest a negative market reaction. Additionally, the potential cannibalization of existing products and delays in benchmarks add to investor concerns.

